Summary:
Rituximab, an anti-CD20 monoclonal antibody, is increasingly used in the treatment of B-cell non-Hodgkin's lymphoma. Late-onset neutropenia in relation to rituximab has been recently described. In this report, we present six cases occurring after stem cell transplantation and discuss the potential impact of this complication.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab, chimeric anti-CD20 Monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.
Voog E, Morschhauser F, Solal-Celigny P . Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348: 2691–2694.
Chaiwatanatorn K, Lee N, Grigg A et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121: 913–918.
Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000; 18: 3025–3030.
Flinn IW, O'Donnell PV, Goodrich A et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transpl 2000; 6: 628–632.
Hequet O, Salles G, Ketterer N et al. Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant 2003; 32: 89–95.
Papadaki T, Stamatopoulos K, Stavroyianni N et al. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leukemia Res 2002; 26: 597–600.
Liu JH, Wei S, Lamy T et al. Chronic neutropenia mediated by fas-ligand. Blood 2000; 95: 3219–3222.
Coakley G, Iqbal M, Brooks D et al. CD8+ CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for neutropenia of Felty's and large granular lymphocyte syndromes. Arthritis Rheum 2000; 43: 834–843.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lemieux, B., Tartas, S., Traulle, C. et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 33, 921–923 (2004). https://doi.org/10.1038/sj.bmt.1704467
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704467
- Springer Nature Limited
Keywords
This article is cited by
-
Late-onset neutropenia following rituximab treatment for rheumatologic conditions
Clinical Rheumatology (2014)
-
Disseminated Cryptococcosis in a Non-Hodgkin’s Lymphoma Patient with Late-Onset Neutropenia Following Rituximab-CHOP Chemotherapy: A Case Report and Literature Review
Mycopathologia (2011)
-
Neutropénie et risque infectieux sous rituximab
Oncologie (2011)
-
Post-autologous stem cell transplantation administration of rituximab improves the outcome of patients with aggressive B cell non-Hodgkin’s lymphoma
Annals of Hematology (2010)
-
A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
Bone Marrow Transplantation (2009)